+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AV-380, an immunoglobulin G1 monoclonal antibody designed to bind human growth differentiation factor 15 GDF-15, a cytokine involved in cancer-induced cachexia. This phase 1B open-label dose escalation study aims to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of AV-380 in cancer patients who have cachexia and elevated GDF-15 levels. Participants have metastatic solid tumors and are actively receiving standard of care chemotherapy. Participants receive AV-380 through intravenous infusion in ascending dose cohorts alongside their standard chemotherapy treatments. The study includes a dose escalation phase where the safety and appropriate dosage of AV-380 are evaluated. This phase allows researchers to monitor the effects of increasing doses of AV-380 over a study period of up to 4 months while patients continue their usual cancer therapies. During the study, participants will undergo assessments including monitoring for adverse events, toxicity, and laboratory abnormalities from enrollment until about 60 days after the last dose. Pharmacokinetic measures such as maximum concentration Cmax, time to maximum concentration Tmax, and area under the curve AUC will also be evaluated. The total involvement includes regular evaluations to track safety, drug behavior in the body, and immune responses to AV-380.

Age: 18Years +All GendersPhase 1
12 locations
S

Actively Recruiting

Researchers are evaluating the use of a dexamethasone mouthwash to prevent stomatitis, a painful mouth condition, in patients receiving Datopotamab Deruxtecan Dato-DXd treatment for certain types of breast cancer or EGFR-mutated non-small cell lung cancer. This Phase IV study focuses on the incidence and severity of grade 2 or higher stomatitis within the first 12 weeks of Dato-DXd treatment. The study involves two groups one with breast cancer and the other with lung cancer, enrolling about 100 participants in total. Participants will use an alcohol-free dexamethasone mouthwash, 0.5 mg per 5 mL, four times daily by swishing 10 mL for about 2 minutes and then spitting it out without swallowing. They must avoid food or drink for at least 30 minutes after use. This mouthwash will be used throughout their standard care treatment with Dato-DXd. The study will follow participants for at least 12 weeks after starting treatment, with additional safety monitoring for about 21 months. During the study, participants will be assessed for the occurrence and severity of stomatitis, adherence to mouthwash use, and any dose changes of Dato-DXd due to stomatitis. Researchers will monitor safety and tolerability of the treatment combination through clinical evaluations, including documentation of side effects. Participants will be followed for safety up to 28 days after their last dose and may be monitored for up to 21 months to observe long-term outcomes.

Age: 18Years +All GendersPhase 4
41 locations
L

Actively Recruiting

Researchers are conducting a 10-year observational study called the Congenital Muscle Disease Patient and Proxy Reported Outcome Study CMDPROS. This study aims to collect and analyze care data and adverse events for various congenital muscle diseases using the Congenital Muscle Disease International Registry CMDIR. The study focuses on individuals with diagnoses such as congenital muscular dystrophy, congenital myopathy, congenital myasthenic syndrome, and related conditions, including those without genetic confirmation. Understanding these conditions better will help improve care standards and support future clinical trials. Participants register in the CMDIR by providing demographic information and completing an intake survey. They are also asked to share medical records related to their diagnosis and treatment, such as genetic testing results, muscle biopsy reports, pulmonary function tests, sleep studies, clinic notes, and hospital discharge summaries. The study collects data on multiple disease subtypes and tracks various health events and care parameters over time, aiming to build a comprehensive database. Throughout the study, participants provide ongoing information about their health status and adverse events, which researchers verify using medical records. Key outcomes include survival rates, hospitalization frequency, respiratory complications, and other health complaints. The study will also analyze measures like ejection fraction, lung function, sleep study results, growth, fractures, and bone density. Data collected will contribute to evidence-based care guidelines and help identify meaningful outcomes for future clinical trials. Participation requires no travel as data collection is done remotely through the registry.

All AgesAll Genders
1 location
M

Actively Recruiting

This research aims to identify hidden small airways obstruction in children and adults with cystic fibrosis who have normal results on routine pre-bronchodilator lung function tests. It focuses on patients with both heterozygous and homozygous cystic fibrosis and explores the presence of lung issues not detected by usual spirometry measures like FEV1, FVC, and their ratios. The study builds on previous findings that small airways obstruction and emphysema can exist despite normal routine lung function tests. Participants undergo diagnostic tests including spirometry and lung CT scans to detect abnormal expiratory airflow at low lung volumes, which may indicate small airways obstruction or peripheral airway bronchiectasis. The study is retrospective and observational, assessing maximal expiratory flow volume loops at 75% and 80% expired lung volume to find airway limitations that routine tests might miss. During the study, researchers analyze existing lung function data and imaging results to measure small airway obstruction in cystic fibrosis patients. The main outcome is the detection of unsuspected small airway obstruction over a 5-year period. Participants routine spirometry results are reviewed alongside specialized measurements to better understand lung function in this population, helping to inform future diagnosis and management strategies.

Age: 5Years - 40YearsAll Genders
2 locations
S

Actively Recruiting

Researchers are studying chronic, stable asthmatics who do not smoke, focusing on understanding what causes expiratory airflow limitation in moderate to severe persistent asthma. This research aims to identify whether the large or small airways mainly contribute to airflow problems and to explore the role of small airway obstruction and loss of lung elastic recoil. The study also evaluates how different doses of inhaled corticosteroids affect inflammation in these airways, using exhaled nitric oxide as a marker. Measurements will also be taken during naturally occurring asthma exacerbations for comparison. Participants receive treatment with inhaled corticosteroids and long-acting beta2-agonists such as fluticasonesalmeterol or budesonideformoterol in varying doses. This is an observational study where additional treatments might include antibiotics and tapering corticosteroids. Researchers will also perform lung function studies, imaging including high-resolution CT scans, and fiberoptic bronchoscopy with optical coherence tomography to assess lung structure and function. During the study, participants will undergo regular assessments including spirometry, measurements of exhaled nitric oxide, and lung function tests over periods ranging from 20 to 60 days and up to 5 years. Data from lung autopsies of asthmatics will be compared when available. The study monitors mechanisms of airflow limitation and presence of emphysema, aiming to better understand the disease process. Participants are observed without masking or randomization, and the total follow-up can extend from months to years.

Age: 10Years - 80YearsAll GendersPhase 4
1 location
S

Actively Recruiting

This research aims to understand the causes and sites of expiratory airflow limitation in people with moderate to severe persistent asthma who are stable, treated, and non-smokers. The study focuses on whether airflow limitation mainly occurs in large or small airways and how much is due to airway obstruction or loss of lung elastic recoil. Researchers will use markers like exhaled nitric oxide to assess airway inflammation and will also study lung changes during asthma flare-ups and stable periods, including detailed imaging and tissue analysis when available. Participants will receive treatment with one of three inhaled corticosteroid and long-acting beta2-agonist combinations fluticasonesalmeterol, budesonideformoterol, or mometasoneformoterol, combined with tiotropium daily. For acute flare-ups, albuterol and ipratropium will be used as needed. The study includes measurements of lung function and quality of life questionnaires. Imaging such as high-resolution CT scans and optical coherence tomography will be performed to evaluate lung structure and detect emphysema. During the study, participants will undergo tests including spirometry with special gas mixtures to locate airflow limitation and exhaled nitric oxide measurements to monitor inflammation over 20 to 60 days. Researchers will also analyze lung tissue from autopsies or transplants when available. The main outcomes include assessing airway inflammation, airflow limitation sites, lung elastic recoil loss, and the presence and extent of emphysema. The study runs until June 2027, with detailed evaluations during stable periods and exacerbations.

Age: 10Years - 95YearsAll Genders
1 location
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are investigating the site and mechanisms responsible for expiratory airflow limitation in people who have chronic obstructive pulmonary disease COPD, emphysema, or asthma-COPD overlap. The study focuses on current or former smokers with a history of more than 15 pack years who have mild to severe expiratory airflow limitation. It aims to understand whether airflow limitation is due to problems in large central airways, small peripheral airways, loss of lung elastic recoil, or a combination of these factors. Participants will undergo extensive lung function tests including spirometry before and after inhaled bronchodilation, lung volume measurements, diffusing capacity, and lung elasticity assessment involving an esophageal balloon. Imaging studies include high-resolution CT scans of the lungs to measure emphysema and bronchiectasis. Blood tests and possibly bronchoscopy may also be performed to gather additional information. The study groups are categorized based on clinical, pathologic, laboratory, physiological, and radiological differences. During the study, participants will have assessments including lung function tests, blood tests, exhaled nitric oxide measurement, and imaging scans. Some tests may be uncomfortable but are expected to cause no harm. The primary measurement is to identify the site and mechanisms of expiratory airflow limitation over a four-year period. The study started in 2017 and is planned to continue through 2027, with participant involvement varying depending on the tests performed.

Age: 30Years +All Genders
2 locations
E

Actively Recruiting

Researchers are evaluating BMS-986368, a FAAHMAGL inhibitor, for its effects on agitation in people with Alzheimers disease. This Phase 2, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, and tolerability of this oral medication in participants aged 55 to 90 years who meet specific diagnostic and agitation criteria. Participants will be randomly assigned to one of three groups receiving either one of two doses of BMS-986368 or a placebo. The study medication is given orally on specified days during an 8-week treatment period. The trial includes a triple-blind design to ensure unbiased evaluation of outcomes. During the study, participants will be assessed for changes in agitation using tools like the Cohen-Mansfield Agitation Inventory CMAI and other behavioral scales up to Week 8. Safety will be monitored through adverse event tracking and laboratory tests up to 28 days after the last dose. Plasma levels of the study drug will be measured up to Week 14. The total participation lasts through the treatment and follow-up periods as defined by the study schedule.

Age: 55Years - 90YearsAll GendersPhase 2
77 locations